Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc (NASDAQ: POAI) delivers AI-powered solutions for personalized cancer treatment through its integrated biobank data and machine learning platforms. This news hub provides investors and researchers with essential updates about the company's advancements in precision oncology.
Access real-time information on POAI's FDA-cleared medical systems, clinical trial partnerships, and AI-driven drug discovery milestones. Our curated collection includes earnings reports, technology validations, and strategic collaborations that demonstrate the company's progress in transforming cancer care.
Key updates cover three operational segments: AI-driven tumor modeling from Pittsburgh labs, biopharma contract research developments in Birmingham, and STREAMWAY System adoption in clinical settings. Stay informed about biomarker discovery breakthroughs and peer-reviewed study publications.
Bookmark this page for streamlined access to POAI's verified financial disclosures, scientific presentations, and regulatory filings. Check regularly for updates on how the company's 150,000+ tumor sample database informs next-generation oncology solutions.
Predictive Oncology Inc. (NASDAQ: POAI) announced a reverse stock split of its common stock at a ratio of 1-for-20, effective April 24, 2023, at 12:01 a.m. This decision aims to comply with the minimum bid price requirements for maintaining its listing on the Nasdaq Capital Market. Following the split, the number of outstanding shares will decrease from approximately 79.6 million to about 3.98 million. Stockholders’ interests will remain proportionate, although fractional shares will be rounded up. The reverse split was authorized by stockholders on April 19, 2023, during a special meeting. The company also noted that there will be proportional adjustments to equity awards, convertible preferred stock, and warrants.
Predictive Oncology (POAI) has announced that its Special Meeting of Stockholders, scheduled for April 17, 2023, was adjourned due to insufficient quorum. The meeting is set to reconvene on April 19, 2023, to discuss a proposal for a reverse stock split ranging from 1-for-2 to 1-for-25. Stockholders of record as of March 28, 2023, are eligible to vote, and previous proxies will be honored at the reconvened meeting. The company is actively soliciting additional votes to ensure the proposal's approval.
Predictive Oncology aims to leverage its AI platform, PEDAL, and a biorepository of tumor samples to enhance drug discovery for cancer treatment. The company emphasizes the importance of stockholder participation in the upcoming vote.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
